Bufalin induced apoptosis in MCF-7 cells, as evidenced by elevated Annexin V-positive populations. In HepG2 cells, RNA sequencing showed upregulated and downregulated genes after Bufalin treatment. In bone marrow-derived macrophages incubated in Hepa1-6 conditioned medium, Bufalin priming increased the IL-12/IL-10 ratio compared with vehicle priming. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Apoptosis in MCF-7 cells
Cell-based study · MCF-7 cells [1]
MCF-7 cells were treated with Bufalin. Treatment induced apoptosis, as evidenced by elevated Annexin V-positive populations.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 or 50 nM
- Exposure duration
- 48 h
- Reported limits
- Not stated in the sentences used: route, vehicle, control.
Methods and source locations
Compound reported in the paper: Bufalin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Bufalin’s anti-cancer effects in ER+ cells are dependent on ERα (S70); Methods > Flow-cytometric analysis of apoptosis (S172); Fig. 6 legend (S280)
apoptosis was examined by measuring Annexin V staining: apoptosis was examined by measuring Annexin V staining — Results > Bufalin’s anti-cancer effects in ER+ cells are dependent on ERα (S70); Fig. 6 legend (S280)
Gene expression changes in liver cancer cells
Cell-based study · HepG2 cells [2]
HepG2 cells were treated with Bufalin at 400 nM for 12 h, with vehicle as the control. RNA sequencing showed that 3000 genes were upregulated and 2450 genes were downregulated after treatment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 400 nM
- Exposure duration
- 12 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Bufalin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > E2F2 degradation regulates the transcription of oncogenic genes (S192, S193); Fig. 6 legend (S238)
RNA sequencing: RNA sequencing; comparator: vehicle (control group) — Results > E2F2 degradation regulates the transcription of oncogenic genes (S192, S193)
Cytokine ratio changes in bone marrow-derived macrophages
Cell-based study · Bone marrow-derived macrophages (BMDMs) were isolated from the femurs of C57BL/6 mice [3]
Bone marrow-derived macrophages from C57BL/6 mice were incubated with Bufalin or vehicle in Hepa1-6 conditioned medium for 48 hours in a design including recombinant M-CSF. The IL-12/IL-10 ratio increased from 0.3 to 8 with Bufalin priming compared with vehicle priming.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 hours
- Method
- incubated with bufalin or vehicle in the Hepa1-6 CM
- Co-treatment
- Other interventions in this design: Hepa1-6 conditioned medium (CM); recombinant M-CSF 20 ng/mL. Compound effect isolated by the comparison: vehicle-primed or bufalin-primed macrophages.
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Bufalin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Generation of bone marrow-derived macrophages and macrophage polarization (S25); Results > Bufalin reprograms M2 macrophages to M1 (S77, S81); Figure 3 legend (S159, S164)
The levels of interleukin (IL)-12 and IL-10 in the supernatant of vehicle-primed or bufalin-primed macrophages were measured by ELISA, and the IL-12/IL-10 ratio was calculated.: The levels of interleukin (IL)-12 and IL-10 in the supernatant of vehicle-primed or bufalin-primed macrophages were measured by ELISA, and the IL-12/IL-10 ratio was calculated.; comparator: vehicle-primed — Results > Bufalin reprograms M2 macrophages to M1 (S81); Figure 3 legend (S164)